News The latest from Lumen Seattle biotech startup Lumen Bioscience raises $11.2M to develop drugs using algae The financing allows Lumen Bioscience to continue developing technology that uses the algae spirulina to make biologics. Spirulina platform Lumen large as firm bags series A, therapies and more ahead Spirulina platform Lumen large as firm bags series A, therapies and more ahead Lumen Wins Grant to Develop Ultra-Low-Cost Therapeutics for Treating Infant Diseases in Developing Countries Lumen to collaborate with Tufts University researchers on proof of concept study for developing world infants Lumen Wins Triple Funding Boost to Advance Development of Low-Cost Therapeutics for Newborns and Infants in Developing Countries Encouraging early antibody research triggers funding increase Dr. Craig Behnke Joins Lumen Bioscience as SVP, Production and Development Dr. Behnke to oversee scale-up of Lumen’s cGMP production facility and continuous process improvement programs Lumen Bioscience Announces Issuance of US Patent for Genetic Modification of Spirulina Broad composition-of-matter claims cover all products currently in development by Lumen. Pagination First page « First Pagination_arrow Previous page ‹ Previous Page 1 Current page 2 Page 3 Pagination_arrow Next page Next › Last page Last »
